Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.

Literature DB >> 2878680

A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.

J W Lammers, M E Müller, H T Folgering, C L van Herwaarden.

Abstract

The effects of single oral doses of atenolol 50 mg and xamoterol 200 mg (a recently developed partial beta 1-adrenoceptor agonist) on lung function, heart rate and blood pressure were investigated in 11 patients with asthma. Xamoterol caused a significant increase in heart rate and systolic blood pressure, which changes are consistent with the partial beta 1-adrenoceptor agonist activity of this drug. Atenolol induced a significant decrease in FEV1 and the forced vital capacity (FVC); there was a non-significant change in FEV1 and FVC after xamoterol. There was no significant difference between the effects of atenolol and xamoterol of FEV1 and FVC. Bronchospasm induced by atenolol 50 mg and xamoterol 200 mg was completely reversed by inhalation of the beta 2-adrenoceptor agonist terbutaline to a cumulative dose of 4.0 mg.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1986 PMID： 2878680 PMCID： PMC1401187 DOI： 10.1111/j.1365-2125.1986.tb02940.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

18 in total

1. Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors: A Melander; K Danielson; B Scherstén; E Wåhlin
Journal: Clin Pharmacol Ther Date: 1977-07 Impact factor: 6.875

2. Coexistence of beta1 and beta2 adrenoceptors in mammalian lung: evidence from direct binding studies.

Authors: E L Rugg; D B Barnett; S R Nahorski
Journal: Mol Pharmacol Date: 1978-11 Impact factor: 4.436

3. Comparative study of the ventilatory effects of three beta 1-selective blocking agents in asthmatic patients.

Authors: A P Greefhorst; C L van Herwaarden
Journal: Eur J Clin Pharmacol Date: 1981 Impact factor: 2.953

4. Diurnal rhythms in airway obstruction.

Authors: C K Connolly
Journal: Br J Dis Chest Date: 1979-10

5. Deposition of pressurized suspension aerosols inhaled through extension devices.

Authors: S P Newman; F Morén; D Pavia; F Little; S W Clarke
Journal: Am Rev Respir Dis Date: 1981-09

6. Effect of prenalterol in asthmatic patients.

Authors: C G Löfdahl; N Svedmyr
Journal: Eur J Clin Pharmacol Date: 1982-10 Impact factor: 2.953

7. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors: A Nuttall; H M Snow
Journal: Br J Pharmacol Date: 1982-10 Impact factor: 8.739

8. Beta-adrenergic blockade of the lung. Dose-dependent cardioselectivity of tolamolol in asthma.

Authors: G M Fleming; E H Chester; H J Schwartz; P K Jones
Journal: Chest Date: 1978-06 Impact factor: 9.410

9. Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

Authors: W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal: Br J Clin Pharmacol Date: 1978-02 Impact factor: 4.335

A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.

1. Enhancement of the bioavailability of propranolol and metoprolol by food.

2. Coexistence of beta1 and beta2 adrenoceptors in mammalian lung: evidence from direct binding studies.

3. Comparative study of the ventilatory effects of three beta 1-selective blocking agents in asthmatic patients.

4. Diurnal rhythms in airway obstruction.

5. Deposition of pressurized suspension aerosols inhaled through extension devices.

6. Effect of prenalterol in asthmatic patients.

7. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

8. Beta-adrenergic blockade of the lung. Dose-dependent cardioselectivity of tolamolol in asthma.

9. Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

10. Cardioselectivity of atenolol in asthmatic patients.

1. Is xamoterol safe in chronic airflow obstruction?

Review 2. Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Review 3. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Review 4. Long-term studies with xamoterol in heart failure.

Review 5. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.